

Contents

Prologue	VII
Acknowledgement	IX
Contributors	XIII
1 Introduction	1
<i>D.K. Stavrou (Hamburg, Germany)</i>	
2 General considerations	
2.1 Tumour-specific and tumour-associated antigens	7
<i>V. Rebmann and H Grosse-Wilde (Essen, Germany)</i>	
2.2 Immunological mechanisms of tumour cell destruction	23
<i>V. Rebmann and H Grosse-Wilde (Essen, Germany)</i>	
2.3 Nonrandom immune escape of glioma cells by immune editing	33
<i>K.S. Zänker (Witten, Germany)</i>	
3 Brain tumour immunology	
3.1 CNS – immune system interplay under normal and pathological conditions	41
<i>M. Mittelbronn (Frankfurt a. Main, Germany) and R. Meyermann (Tübingen, Germany)</i>	
3.2 Expression of brain associated antigens in neuroepithelial cells	63
<i>D.K. Stavrou (Hamburg, Germany)</i>	
3.3 Immune biology of microglia in gliomas	69
<i>M.B. Graeber (Sydney, Australia), A. Flügel (Göttingen, Germany), L.B. Moran (London, UK), and B.W. Scheithauer (Rochester, USA)</i>	
3.4 HLA class I antigen, antigen processing machinery component and NK cell ligand changes in astrocytic tumors: molecular mechanisms and clinical implications	81
<i>M. Campoli (Denver, USA) and S. Ferrone (Pittsburgh, USA)</i>	
3.5 Immune status of glioma patients	103
<i>C. Hagel (Hamburg, Germany)</i>	

4 Glioma associated antigens

- 4.1 Glioma associated antigens in experimental rat brain tumours defined by monoclonal antibodies **111**
D.K. Stavrou (Hamburg, Germany)
- 4.2 Monoclonal antibody treatment of experimental Gliomas **123**
D.K. Stavrou (Hamburg, Germany)
- 4.3 Glioma cell lines established from human brain tumours **131**
E. Giannopoulou, A.G. Antonacopoulou and H.P. Kalofonos (Rion-Patras, Greece)
- 4.4 Generation of monoclonal antibodies against human glioma associated antigens and their clinical relevance **153**
D.K. Stavrou (Hamburg, Germany)
- 4.5 Expression of glioma associated antigens in human gliomas and glioma cell lines demonstrated by monoclonal antibodies **165**
C. Hagel (Hamburg, Germany)
- 4.6 Optimizing monoclonal antibodies for application in patients **181**
C. Hagel (Hamburg, Germany)

5 Radioimmunosciintigraphy of gliomas

- 5.1 Radioimmunoimaging of human glioma xenografts in athymic nude mice **195**
D.K. Stavrou (Hamburg, Germany)

6 Applications of monoclonal antibodies in clinical neurooncology

- 6.1 Inhibition of glioma angiogenesis by monoclonal antibodies **205**
A.A. Argyriou and H.P. Kalofonos (Rion-Patras, Greece)
- 6.2 Radioimmunodetection and radioimmunotherapy of human gliomas . . **219**
C.A. Kousparou (Nicosia, Cyprus and London, UK) and A.A. Epenetos (London/UK)